Skip to Content
COVID-19 Resources
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 10/28/16

Newsletter No. 98 — November 2007


Release Date: October 12, 2007
Letters of Intent Receipt Date: December 24, 2007
Application Receipt Date: January 24, 2008
This Funding Opportunity Announcement (FOA) issued by the Cancer Imaging Program of the NCI is an open competition initiative, designed to continue the efforts of the NCI to develop and translate cancer-relevant optical imaging technologies as a part of an overall imaging program for early cancer detection, diagnosis, therapeutic response, drug development, and image-guided therapy. This FOA stems from the previous initiative on optical imaging technology, but the program structure and goals of the current FOA differ from those of the original program. Accordingly, all responses to this FOA will be considered new applications, with the main objective being to accelerate the translational research of in vivo multimodal imaging and/or spectroscopic platforms from the laboratory and pre-clinical level to the clinical level. Applications are sought from multi-disciplinary, multi-institutional research teams. After the awards, successful teams will become Centers that will be organized into an interactive network. The network will be called the "Network for Translational Research: Optical Imaging" (NTR). The purpose of NTR is to develop, optimize, and validate imaging technology platforms and methods so that they can enter single or multi-site clinical trials and eventually be incorporated into clinical practice. Applicants responding to this FOA must identify a specific cancer-relevant clinical goal and propose to develop and validate at least one multimodal imaging platform, as defined in this FOA, to address this clinical goal.

Application Receipt Date: December 20, 2007
This Funding Opportunity Announcement (FOA) is designed to support the multidisciplinary training of individuals with background in the basic, biomedical, clinical, and information sciences and/or engineering who are pursuing research that applies the development and application of nanotechnology to the prevention, detection, diagnosis, and/or treatment of cancer. This FOA solicits applications for postdoctoral fellowships from recent doctoral level graduates as well as applications for senior fellowships from candidates with at least 7 years of research experience beyond the doctorate and established independent research positions. The term "nanotechnology", as used in this FOA, refers to devices or base materials that are less than 1000 nm in size (although the assembly, synthesis, and/or fabrication of components at dimensions less than 300 nm should be demonstrated) and may incorporate synthetic materials or biomaterials engineered to provide novel properties or modified functions based on nanoscale size, i.e., nanomaterials. This FOA is a component of the NCI Alliance for Nanotechnology in Cancer (, an integrated 5-year-long initiative to develop and apply nanotechnology to cancer prevention, detection, diagnosis, and treatment, thereby enabling nanotechnology to become a fundamental driver of advances in cancer research and clinical oncology.

Predictive Multiscale Models of the Physiome in Health and Disease (R01) (multiple ICs)(PAR-08-023)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
NIH recognizes the need for sophisticated, predictive, computational models of development and disease that encompass multiple biological scales, designed to uncover biological mechanisms or to make predictions about clinical outcome and drawing on a variety of data sources including relevant clinical data. Ultimately the models and the information derived from their use will enable researchers and clinicians to better understand, prevent, diagnose and treat the diseases or aberrations in normal development. Specifically this FOA solicits the development of predictive multiscale models of health and disease states that must include higher scales of the physiome.

Development and Implementation of Innovative Ultrasound Therapy Technologies (R01) (RFA-EB-07-004) (NIBIB)
Letters of Intent Receipt Date(s): December 23, 2007
Application Receipt Date(s): January 23, 2008
The long-term goal of this initiative is to develop and accelerate the implementation of innovative, disruptive, safe, non-invasive ultrasound technologies that significantly enable or enhance interventional therapies for treatment of diseases, injuries, abnormalities, or other conditions. The successful implementation of the proposed ultrasound intervention technologies should have the potential to greatly mitigate disease and produce a substantial health impact on a large population.

Technology Development in Epigenetics (R21) (RFA-RM-07-012) (Roadmap)
Technology Development in Epigenetics (R01) (RFA-RM-07-011) (Roadmap)

Letters of Intent Receipt Date(s): January 14, 2008
Application Receipt Date(s): February 14, 2008
The NIH invites qualified investigators from academic or research institutions to submit an application for this Funding Opportunity Announcement (FOA) whose goal is to stimulate the development of revolutionary epigenetics technologies. Transforming technologies are needed to enable researchers to discover, monitor and catalogue epigenetic events, changes, and alterations related to development and disease. This FOA focuses on innovative research developing new technologies that will significantly change the way that epigenetics research can be performed.
URL for R21:
URL for R01:

Other Agencies

AAPM Fellowship for Graduate Study in Medical Physics
Application deadline: April 15, 2008

The Cancer Imaging Program of the NCI requests submissions for its Development of Clinical Imaging Drugs and Enhancers (DCIDE) initiative. The goal is the rapid movement of promising, novel cancer imaging enhancers or molecular probes from the laboratory to proof of principle clinical trials. See the web site for details.

The Molecular Imaging and Contrast Agent Database (MICAD) program has been developed as a key component of the NIH Molecular Imaging Roadmap to provide freely accessible online scientific information on in vivo molecular imaging and contrast agents. To accelerate expansion of the database to include all published agents, the MICAD program has implemented a procedure for members of the imaging community to write and submit entries (chapters) as guest authors to the database. All members of the imaging community are encouraged to consider this guest author opportunities. For further information, please contact the MICAD staff at Individual guest authors will be provide with detailed instructions, style guidelines, and a chapter template. The name of the contributing author(s) will be acknowledged and included in the MICAD online publication.


January 17-19, 2008, Bethesda North Convention Center, Rockville, MD

RSNA Grant Writing Course - Writing a Competitive Grant Proposal
Feb 1,2, 2008 Oak Brook, IL; Registration deadline: December 21st, 2007

ISMRM 16th Scientific Meeting & Exhibition, Toronto, ON, Canada
May 3-9, 2008, Toronto, ON, Canada.

The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.

If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail ( Please include your complete mailing address, title, phone and fax numbers.

Cancer Imaging Program
Division of Cancer Treatment and Diagnosis, NCI
6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507